“Statistically significant improvements in lung function, symptoms and quality of life 36% reduction in rate of exacerbations over 24 weeks Well tolerated safety profile over 48 weeks NDA submission planned for 1H 2023” Oh, 48 weeks! !

Anavex said that the candidate's safety profile also appeared to be relatively good.

Anavex also better in ADAS-Cog14, and far superior safety profile.

>> no clinically significant treatment-related adverse events and no serious adverse events = PERFECT SAFETY PROFILE !!

$AVXL safety profile = excellent !!

with Blarcamesine's outstanding safety profile this will become the #1 off label prescribed drug in the world.

$AVXL for Hans, yes $avxl is great and will get approved when it’s high dose arm absolutely crushes the current SOC with a flawless safety profile.

Blood thinner Eliquis captured significant market from Xarelto due to its safety profile.

$TGTX paid troll for Goldman or BOA, superb labeling with excellent safety profile and no warning

Imagine how much Ubli could be worth to BP now with Briumvi’s best in class product profile.

Clear best in class profile, less of a burdensome for pts, less time at care centers and less expensive for providers.

YouTube link in my profile bio. Arc community is a helpful and friendly community filled with triple digit track record traders & educational content, free community room (link in bio)